A Gatekeeping Role of ESR2 to Maintain the Primordial Follicle Reserve

Endocrinology. 2020 Apr 1;161(4):bqaa037. doi: 10.1210/endocr/bqaa037.

Abstract

Over the entire reproductive lifespan in mammals, a fixed number of primordial follicles serve as the source of mature oocytes. Uncontrolled and excessive activation of primordial follicles can lead to depletion of the ovarian reserve. We observed that disruption of estrogen receptor β (ESR2) signaling results in increased activation of primordial follicles in Esr2-null (Esr2-/-) rats. However, follicle assembly was unaffected, and the total number of follicles remained comparable between neonatal wild-type and Esr2-/- ovaries. While the activated follicle counts were increased in Esr2-/- ovary, the number of primordial follicles were markedly decreased. Excessive recruitment of primordial follicles led to premature ovarian senescence in Esr2-/- rats and was associated with reduced levels of serum AMH and estradiol. Disruption of ESR2 signaling through administration of a selective antagonist (PHTPP) increased the number of activated follicles in wildtype rats, whereas a selective agonist (DPN) decreased follicle activation. In contrast, primordial follicle activation was not increased in the absence of ESR1, indicating that the regulation of primordial follicle activation is ESR2 specific. Follicle activation was also increased in Esr2 mutants lacking the DNA binding domain, suggesting a role for the canonical transcriptional activation function. Both primordial and activated follicles express ESR2, suggesting a direct regulatory role for ESR2 within these follicles. We also detected that loss of ESR2 augmented the activation of AKT, ERK, and mTOR pathways. Our results indicate that the lack of ESR2 upregulated both granulosa and oocyte factors, which can facilitate AKT and mTOR activation in Esr2-/- ovaries leading to increased activation of primordial follicles.

Keywords: AKT and mTOR pathways; estrogen receptor β (ESR2); mutant rat models; premature ovarian insufficiency; primordial follicle activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Mullerian Hormone / blood*
  • Estradiol / blood*
  • Estrogen Receptor Modulators / pharmacology
  • Estrogen Receptor beta / agonists
  • Estrogen Receptor beta / antagonists & inhibitors
  • Estrogen Receptor beta / genetics*
  • Estrogen Receptor beta / metabolism
  • Female
  • Mechanistic Target of Rapamycin Complex 1
  • Nitriles / pharmacology
  • Ovarian Follicle / drug effects
  • Ovarian Follicle / metabolism*
  • Ovarian Reserve / drug effects
  • Ovarian Reserve / physiology*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Transgenic
  • Signal Transduction / drug effects

Substances

  • 2,3-bis(4-hydroxyphenyl)-propionitrile
  • 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol
  • Estrogen Receptor Modulators
  • Estrogen Receptor beta
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • Estradiol
  • Anti-Mullerian Hormone
  • Mechanistic Target of Rapamycin Complex 1